Company profile: ProstaGene
1.1 - Company Overview
Company description
- Provider of biotechnology solutions integrating proprietary molecular diagnostics with novel therapeutic screening and commercial experience to develop novel cancer treatments, based on the patents of founder Dr. Richard G. Pestell; early-stage.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ProstaGene
BioImagene
HQ: United States
Website
- Description: Provider of digital pathology solutions for clinical diagnostics and drug discovery, delivering integrated hardware and software systems to acquire, view, share, manage, archive, and analyze tissue images in pathology laboratories, including IHC algorithms such as HER2, ER/PR, and p53.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioImagene company profile →
Novian Health
HQ: United States
Website
- Description: Provider of proprietary interstitial laser therapy solutions for the focal destruction of breast tumors, including Novilase Breast Therapy, the Interstitial Laser System for breast-conserving procedures, and evidence-generation programs such as the ABLATE Registry and BR-003 clinical trial to support reimbursement and U.S. marketing clearance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novian Health company profile →
EMulate Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage therapeutic devices using proprietary ultra-low radio frequency energy (ulRFE) to elicit therapeutic biological effects. Programs include clinical testing in brain cancer and preclinical work in pain and mental health, advanced by subsidiaries: Cellsana (oncology; Phase III prep for glioblastoma/diffuse midline glioma), Mensana (mental health; Phase I prep), and Indolor (pain; Phase I prep).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EMulate Therapeutics company profile →
Turning Point Therapeutics
HQ: United States
Website
- Description: Provider of structure-based drug discovery and development of precision medicines for cancer and other diseases, focusing on novel chemical identities for established oncogene drivers with secondary resistant mutations and newly identified disease-driven targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Turning Point Therapeutics company profile →
Onxeo
HQ: France
Website
- Description: Provider of oncology drug R&D and platforms, offering Beleodaq (belinostat), a histone deacetylase inhibitor marketed in the US for injection; Livatag, a nanoparticle doxorubicin in Phase III for primary liver cancer; and pipeline programs including platON, a decoy oligonucleotide platform for cancer and inflammatory diseases; AsiDNA, a DNA-repair decoy; and VIO-01, a pan‑DDR decoy activating STING.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Onxeo company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ProstaGene
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ProstaGene
2.2 - Growth funds investing in similar companies to ProstaGene
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ProstaGene
4.2 - Public trading comparable groups for ProstaGene
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →